Skip to main content
Contact Us
Subscribe
E-Edition
63°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
October 29, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
October 23, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
October 22, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Tim Buckley Elected to Pfizer’s Board of Directors
October 15, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
October 11, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
October 10, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Fourth-Quarter 2024 Dividend
October 09, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024
October 08, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
September 25, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
September 17, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
September 14, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
September 14, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
September 11, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
August 28, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare
August 27, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
August 12, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
July 30, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
July 25, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
July 24, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
July 11, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
July 09, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Cyrus Taraporevala Elected to Pfizer’s Board of Directors
July 01, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Declares Third-Quarter 2024 Dividend
June 26, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
June 18, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
June 14, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
June 12, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.